News

Novartis is making significant strides in the field of Charcot-Marie-Tooth (CMT) disease treatments, having recently entered into a substantial $1.3 billion deal with Chong Kun Dang Pharmaceutical Corp (CKD). The South Korean pharmaceutical company announced on November 6th that it ...

New technologies in gene editing such as CRISPR/Cas9 present a promising opportunity for the treatment of genetic diseases like CMT at the root cause – often just a single base pair or “letter” change in the DNA sequence. Research lead ...

First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth Association (CMTA) today announced that it participated in the Seed Series Extension syndicate for Armatus Bio, Inc. (Armatus). Armatus is an emerging biotechnology company that is advancing a unique gene therapy ...

GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced Nov. 6 that Suzanne (Sue) Bruhn, PhD, an accomplished biotech executive with extensive experience in the development and commercialization of treatments for rare diseases, will take the helm of the ...

“The CMTA welcomes this community update from Novartis and applauds its leading role in the development of treatments for CMT. The CMTA has been maintaining regular contact, providing support and feedback to Novartis during this early transition and integration phase. ...